ENHERTU AstraZeneca Pty Ltd
Product name
ENHERTU
Sponsor
Accepted date
Jan-2026
Active ingredients
trastuzumab deruxtecan
Proposed indication
ENHERTU followed by THP (a taxane, trastuzumab, and pertuzumab) is indicated for the neoadjuvant treatment of adult patients with HER2-positive Stage II or III breast cancer.
Application type
C (new indication)
Publication date
Jan-2026